Currently, the most druggable target for neuroblastoma is represented by anaplastic lymphoma kinase (ALK), as activating ALK mutations and amplifications are detected in approximately 10% and 4.5% of neuroblastoma tumors, respectively26. This evidence concerns the gene ALK and neuroblastoma.